JPRN-UMIN000007642招募中未知
PGx-based anti-coagulant therapy with Warfarin Dosing - P-ACTWAD
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who have taken warfarin before. 2) Patients who urgently have to start anti-coagulant therapy. 3) Patients with a history of the prosthetic valve replacement. 4) Patients for whom target INR 2.0-3.0 are inadequate. 5) Patients with a severe hepatic or renal disorder. 6) Patients with thyroid dysfunction. 7) Patients who are applicable to contraindication to warfarin therapy. 8) Patients who take medicines that interact with warfarin. 9) Patients who cannot understand or practice the dietary instruction. 10) Patients judged by investigators as ineligible for study enrollment.
研究者
相似试验
进行中（未招募）
不适用
Antikoagulanttihoito varfariinilla sydäntahdistimen asennuksen yhteydessä - Tahdistin-VarfariiniEUCTR2005-000390-22-FITurku University Hospital400
已完成
不适用
Continuous Warfarin (Antithrombin therapy) administration versus Heparin bridge therapy in post colon polypectomy hemorrhagecolon polypJPRN-UMIN000023720Osaka City University Graduate School of Medicine316
进行中（未招募）
不适用
Anticoagulation with argatroban and prostacyclin compared to unfractionated heparin and prostacyclin during continous venovenous haemodialfiltation: a crossover trialAnticoagulation with argatroban and prostacyclin compared to unfractionated heparin and prostacyclin during continous venovenous haemodiafiltarion: a crossover trialEUCTR2008-000042-31-ATniv. Klinik f. Anästhesie, Intensivmedizin und Schmerztherapie
进行中（未招募）
1 期
During atrial fibrillation catheter ablation procedure treatment with anticoagulant drugs is necessary in order to prevent blood clotting and thereby decrease the risk of procedure related strokes. In this study two different types of anticoagulant drugs are being compared during and after the atrial fibrillation catheter ablation procedure: the novel direct factor Xa inhibitor apixaban and any of the standard vitamin K antagonists.Atrial fibrillation catheter ablationMedDRA version: 19.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.1Level: LLTClassification code 10071667Term: Persistent atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.1Level: LLTClassification code 10003661Term: Atrial fibrillation paroxysmalSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.1Level: LLTClassification code 10066582Term: Recurrent atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2014-002442-45-ATKompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]650
进行中（未招募）
1 期
During atrial fibrillation catheter ablation procedure treatment with anticoagulant drugs is necessary in order to prevent blood clotting and thereby decrease the risk of procedure related strokes. In this study two different types of anticoagulant drugs are being compared during and after the atrial fibrillation catheter ablation procedure: the novel direct factor Xa inhibitor apixaban and any of the standard vitamin K antagonist.EUCTR2014-002442-45-DEKompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)]650